BNO Share Price

Open 0.36 Change Price %
High 0.36 1 Day 0.00 0.00
Low 0.35 1 Week -0.01 -2.70
Close 0.36 1 Month 0.01 2.86
Volume 138478 1 Year -0.12 -25.00
52 Week High 0.50
52 Week Low 0.23
BNO Important Levels
Resistance 2 0.37
Resistance 1 0.37
Pivot 0.36
Support 1 0.35
Support 2 0.35
ASX Australia Most Active Stocks
AKK 0.01 0.00%
GPP 0.03 0.00%
IMU 0.01 0.00%
IMU 0.01 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
DUE 2.74 16.60%
DUE 2.74 16.60%
PDN 0.06 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
AHN 0.04 100.00%
AZS 0.03 50.00%
AZS 0.03 50.00%
PMQ 0.03 50.00%
NGY 0.05 25.00%
BIT 0.05 25.00%
BIT 0.05 25.00%
RAW 0.06 20.00%
RAW 0.06 20.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
BMN 0.02 -33.33%
AZM 0.03 -25.00%
AZM 0.03 -25.00%
AZM 0.03 -25.00%
NMS 0.90 -23.73%
More..

Bionomics Ltd (ASX: BNO)

BNO Technical Analysis 1.5
As on 5th Dec 2016 BNO Share Price closed @ 0.36 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.33 & Sell for SHORT-TERM with Stoploss of 0.39 we also expect STOCK to react on Following IMPORTANT LEVELS.
BNO Target for December
1st Target up-side 0.41
2nd Target up-side 0.44
3rd Target up-side 0.48
1st Target down-side 0.31
2nd Target down-side 0.28
3rd Target down-side 0.24
BNO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.bionomics.com.au
BNO Address
BNO
31 Dalgleish street
Thebarton, SA 5031
Australia
Phone: 61 8 8354 6100
Fax: 61 8 8354 6199
BNO Latest News
Interactive Technical Analysis Chart Bionomics Ltd ( BNO ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Bionomics Ltd
BNO Business Profile
Bionomics Limited, a biotechnology company, discovers and develops innovative therapeutics for the treatment of cancer and disorders of the central nervous system in Australia, France, and the United States. It develops small molecule and antibody programs in the areas of cancer, anxiety and memory loss. The company’s oncology approach includes cancer stem cell therapeutics, as well as vascular disruption in solid tumors. Its product pipeline includes BNC105, a novel compound that potently and selectively restricts blood flow within tumors that is in Phase II clinical trials for the treatment of solid tumors; BNC210, which is under development for the treatment of anxiety disorders; and Kv1.3 blockers for the treatment of multiple sclerosis, rheumatoid arthritis, psoriasis, and other autoimmune conditions. The company’s product pipeline also comprises alpha 7 nicotinic acetylcholine receptor modulators for the treatment of cognitive impairment in Alzheimer's disease and in Parkinson's disease. In addition, the company, through its subsidiary, Neurofit SAS, offers contract research services for various pharmaceutical and biotechnology companies. It has collaboration, research, and licensing agreement with Ironwood Pharmaceuticals, Inc. to develop and commercialize the company’s investigational anti-anxiety compound BNC210 and other related compounds; and a collaboration agreement with Cancer Therapeutics Cooperative Research Center. Bionomics Limited was founded in 1999 and is based in Thebarton, Australia.